Redefining Sight for Life.TM
Contact Us

News & Publications

Stay in the know about our company, science and our aspiration to use gene therapy to restore vision and prevent blindness.

News & Press Releases
View All
Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference
News June 2, 2023
Adverum Biotechnologies Announces New Executive Leadership Roles
News May 25, 2023
Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting
News May 18, 2023
Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform
News May 18, 2023
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
News May 11, 2023
Publications
View All
ASGCT 2023
Presentations May 19, 2023
ASGCT 2023
Presentations May 18, 2023
ASGCT 2023
Presentations May 18, 2023
ASGCT 2023
Presentations May 17, 2023
ASGCT 2023
Presentations May 17, 2023
Sort by Date:
Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference
News| June 2, 2023
Adverum Biotechnologies Announces New Executive Leadership Roles
News| May 25, 2023
Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting
News| May 18, 2023
Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform
News| May 18, 2023
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
News| May 11, 2023
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
News| May 10, 2023
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Program for Geographic Atrophy Secondary to Dry AMD
News| May 2, 2023
Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
News| April 23, 2023
Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD
News| April 18, 2023
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
News| April 17, 2023
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
News| March 30, 2023
Adverum Biotechnologies to Present at Upcoming Investor Conferences
News| February 27, 2023
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News| January 18, 2023
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News| December 6, 2022
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
News| November 10, 2022
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
News| November 4, 2022
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
News| October 27, 2022
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
News| September 30, 2022
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference
News| September 27, 2022
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
News| September 23, 2022
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
News| September 23, 2022
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
News| September 14, 2022
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
News| September 8, 2022
Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
News| August 11, 2022
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference
News| August 10, 2022
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News| August 1, 2022
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
News| July 15, 2022
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022
News| July 8, 2022
Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD
News| July 6, 2022
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
News| June 24, 2022
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD
News| June 9, 2022
Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting
News| June 2, 2022
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy
News| May 19, 2022
Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022
News| May 17, 2022
Adverum Biotechnologies Reports First Quarter 2022 Financial Results
News| May 12, 2022
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News| May 9, 2022
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022
News| May 2, 2022
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting
News| May 1, 2022
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022
News| April 19, 2022
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA
News| April 6, 2022
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
News| March 29, 2022
Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors
News| March 17, 2022
Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference
News| February 28, 2022
Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer
News| February 7, 2022
Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer
News| January 6, 2022
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
News| January 4, 2022
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022
News| December 21, 2021
Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
News| December 6, 2021
Adverum Reports Third Quarter 2021 Results
News| November 4, 2021
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
News| October 9, 2021
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
News| October 1, 2021
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
News| September 27, 2021
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
News| August 23, 2021
Adverum Reports Second Quarter 2021 Results
News| August 5, 2021
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
News| July 22, 2021
Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
News| July 1, 2021
Adverum Announces Changes to Management Team
News| June 24, 2021
Adverum Appoints CMO and CSO
News| June 1, 2021
Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
News| May 12, 2021
Adverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders
News| May 10, 2021
Adverum Reports First Quarter 2021 Results
News| May 6, 2021
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
News| May 1, 2021
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
News| April 28, 2021
Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation
News| April 22, 2021
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
News| April 21, 2021
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 
News| April 16, 2021
Adverum Files Definitive Proxy Materials and Mails Letter to Stockholders Detailing Strength of Team and Acceleration Toward Commercialization of ADVM-022
News| April 15, 2021
Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials
News| March 30, 2021
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News| March 18, 2021
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
News| March 17, 2021
Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results
News| March 1, 2021
Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
News| February 22, 2021
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors
News| February 22, 2021
Adverum Appoints Christopher J. DeRespino as Chief Business Officer
News| February 18, 2021
Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting
News| February 10, 2021
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy
News| February 2, 2021
Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook
News| January 11, 2021
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
News| January 7, 2021
Adverum Biotechnologies to Present at 39th Annual J.P. Morgan Healthcare Conference
News| January 5, 2021
Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors
News| December 14, 2020
Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference
News| November 23, 2020
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
News| November 14, 2020
Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2020 Financial Results
News| November 5, 2020
Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual
News| October 20, 2020
Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science
News| September 15, 2020
Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference
News| September 10, 2020
Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock
News| August 18, 2020
Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
News| August 12, 2020
Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock
News| August 11, 2020
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results
News| August 10, 2020
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update
News| July 29, 2020
Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy
News| July 21, 2020
Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME)
News| July 13, 2020
Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD
News| July 6, 2020
Adverum Biotechnologies Announces Appointment of Heikki Jouttijärvi as Vice President of Manufacturing
News| June 25, 2020
Adverum Biotechnologies Announces Leadership Transition
News| June 15, 2020
Adverum Biotechnologies to Participate in Goldman Sachs 41st Annual Global Healthcare Conference
News| June 4, 2020
Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results
News| May 28, 2020
Adverum Biotechnologies to Host a Conference Call and Webcast to Report First Quarter 2020 Financial Results and Provide Corporate Update
News| May 21, 2020
Adverum Biotechnologies Reports Positive Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
News| May 4, 2020
Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO
News| April 30, 2020
Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
News| April 27, 2020
Adverum Biotechnologies to Host a Conference Call and Webcast to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD
News| April 27, 2020
Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors
News| April 20, 2020
Adverum Biotechnologies Reports Recent Business Progress and Fourth Quarter 2019 Financial Results
News| March 12, 2020
Adverum Biotechnologies Announces Data Presentations at ARVO 2020
News| March 11, 2020
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update
News| March 5, 2020
Adverum Biotechnologies Appoints Angela Thedinga as Chief Technology Officer
News| February 25, 2020
Adverum Biotechnologies to Present at Upcoming Investor Conferences
News| February 19, 2020
Adverum Biotechnologies Announces Closing of $150 Million Public Offering of Common Stock
News| February 14, 2020
Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
News| February 11, 2020
Adverum Biotechnologies Announces $100 Million Public Offering of Common Stock
News| February 10, 2020
Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020
News| February 8, 2020
Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2020 Meeting
News| January 28, 2020
Adverum Biotechnologies Moves to New Headquarters and Expands Laboratory Space in Redwood City, CA
News| January 27, 2020
Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook
News| January 12, 2020
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting
News| January 11, 2020
Adverum Biotechnologies to Present at Upcoming Conferences
News| December 18, 2019
Adverum Biotechnologies to Participate in Piper Jaffray’s 31st Annual Healthcare Conference
News| November 20, 2019
Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2019 Financial Results
News| November 7, 2019
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates
News| October 31, 2019
Adverum Biotechnologies Expands Leadership Team with the Appointment of Peter Soparkar as Chief Legal Officer
News| October 30, 2019
Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
News| October 24, 2019
Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress
News| October 23, 2019
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
News| October 11, 2019
Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
News| September 26, 2019
Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD
News| September 12, 2019
Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting
News| September 4, 2019
Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October
News| August 28, 2019
Adverum Biotechnologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
News| August 8, 2019
Adverum Biotechnologies Announces Board and Senior Management Changes
News| August 1, 2019
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2019 Financial Results and Provide Corporate Updates
News| July 25, 2019
Adverum Biotechnologies Appoints Senior Leaders
News| July 15, 2019
Adverum Biotechnologies to Present Data at Upcoming Conferences
News| July 8, 2019
Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD
News| June 10, 2019
Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD
News| May 16, 2019
Adverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
News| May 8, 2019
Adverum Biotechnologies Announces Board Changes
News| May 2, 2019
Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 Gene Therapy in Wet AMD at the ASGCT 22nd Annual Meeting
News| May 2, 2019
Adverum Biotechnologies Presents First Preclinical Data on Dosing Contralateral Eye with ADVM-022 Gene Therapy for Wet AMD at the ARVO 2019 Annual Meeting
News| April 30, 2019
Adverum Biotechnologies Appoints Thomas Leung as Chief Financial Officer
News| April 24, 2019
Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO
News| April 16, 2019
Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD
News| April 15, 2019
Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer
News| April 1, 2019
Adverum Biotechnologies to Participate in Upcoming Conferences
News| March 18, 2019
Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
News| March 6, 2019
Adverum to Present at the Cowen 39th Annual Health Care Conference
News| February 28, 2019
Adverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference
News| February 13, 2019
Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference
News| February 11, 2019
Adverum Biotechnologies Provides 2019 Outlook
News| January 6, 2019
Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference
News| December 20, 2018
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
News| December 3, 2018
Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
News| December 3, 2018
Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
News| November 19, 2018
Adverum to Present at 30th Annual Piper Jaffray Healthcare Conference
News| November 13, 2018
Adverum Biotechnologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
News| November 8, 2018
Adverum Biotechnologies Provides Program Updates
News| November 1, 2018
Adverum Biotechnologies Announces Data Presented at the European Society of Gene and Cell Therapy (ESGCT)
News| October 17, 2018
Adverum Biotechnologies Announces Appointment of Leone Patterson as CEO and Member of the Board of Directors
News| October 17, 2018
Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD
News| September 19, 2018
Adverum to Present at Cantor Global Healthcare Conference
News| September 18, 2018
Adverum Biotechnologies Announces IND Active for ADVM-022, a Novel Gene Therapy to Treat Wet Age-related Macular Degeneration
News| August 29, 2018
Adverum Biotechnologies Receives Orphan Drug Designation for ADVM-053, a Novel Gene Therapy Candidate for the Treatment of Hereditary Angioedema
News| August 24, 2018
Adverum Biotechnologies Reports Second Quarter 2018 Financial Results and Provides Corporate Update
News| August 8, 2018
Adverum Biotechnologies Announces Clinical Progress Across Gene Therapy Pipeline
News| August 1, 2018
Adverum Biotechnologies Appoints Katherine Bock as Vice President, Investor Relations & Corporate Communications
News| July 24, 2018
Adverum Biotechnologies to Present at the 2018 Jefferies Global Healthcare Conference
News| June 4, 2018
Adverum Biotechnologies Presents Additional Long-term Preclinical Data on ADVM-022 in Wet AMD at ASGCT 21st Annual Meeting
News| May 17, 2018
Adverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate Update
News| May 9, 2018
Adverum Biotechnologies Announces Leadership Changes
News| May 3, 2018
Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD
News| May 1, 2018
Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update
News| March 6, 2018
Adverum Biotechnologies to Present at Upcoming Investor Conferences
News| February 26, 2018
Adverum Biotechnologies Announces Completion of Dosing of First Cohort of Patients in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 Gene Therapy for A1AT Deficiency
News| February 26, 2018
Adverum Biotechnologies Announces Closing of $69 Million Public Offering
News| February 12, 2018
Adverum Biotechnologies Announces Pricing of $60 Million Public Offering of Common Stock
News| February 8, 2018
Adverum Biotechnologies Announces Proposed Public Offering of Common Stock
News| February 7, 2018
Adverum Biotechnologies and Editas Medicine Extend Research Collaboration
News| January 25, 2018
Adverum Biotechnologies Provides 2018 Outlook
News| January 4, 2018
Adverum Biotechnologies Doses First Patient in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 for A1AT Deficiency
News| December 28, 2017
Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT Deficiency
News| December 5, 2017
Adverum Biotechnologies to Present at Upcoming Conferences
News| November 15, 2017
Adverum Biotechnologies Reports Third Quarter 2017 Financial Results and Provides Corporate Update
News| November 8, 2017
Adverum Biotechnologies Appoints Linda Neuman, M.D. as Vice President, Clinical Development
News| October 2, 2017
Adverum Biotechnologies to Present at Upcoming Conferences
News| September 28, 2017
Adverum Biotechnologies Presents Updated Preclinical Data on ADVM-022 in Wet AMD at the 2017 Targeting Ocular Disorders Conference
News| September 27, 2017
Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors
News| September 7, 2017
Adverum Biotechnologies to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
News| September 7, 2017
Adverum Biotechnologies Reports Second Quarter 2017 Financial Results and Provides Update
News| August 8, 2017
Adverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chief Medical Officer
News| June 20, 2017
Adverum Biotechnologies to Present at the Jefferies Global Healthcare Conference
News| May 22, 2017
Adverum Biotechnologies, Inc. Announces Data Presentations at the ARVO and ASGCT 2017 Annual Meetings
News| May 10, 2017
Adverum Biotechnologies Reports First Quarter 2017 Financial Results and Provides Update
News| May 9, 2017
Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors
News| April 20, 2017
Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day
News| April 17, 2017
Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
News| April 6, 2017
Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors
News| March 14, 2017
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Update
News| March 6, 2017
Adverum Biotechnologies to Present at Upcoming Investor Conferences
News| February 21, 2017
Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017
News| January 18, 2017
Adverum Biotechnologies to Present at Upcoming Investor Conferences
News| November 9, 2016
Adverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results
News| November 8, 2016
Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) Meeting
News| October 20, 2016
Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO
News| October 14, 2016
Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program
News| October 14, 2016
Adverum Biotechnologies to Present at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting
News| October 13, 2016
Adverum Biotechnologies Presents Preclinical Data on Novel Gene Therapy Candidates for the Treatment of Wet AMD at The Retina Society 2016 Annual Meeting
News| September 16, 2016
Adverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye
News| August 9, 2016
Adverum Biotechnologies, Inc. Reports Second Quarter 2016 Financial Results
News| August 9, 2016
Adverum Biotechnologies Provides wet AMD Program Update
News| July 7, 2016
Adverum Biotechnologies Appoints Leone Patterson as Chief Financial Officer
News| June 13, 2016
Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies
News| May 12, 2016
Avalanche Biotechnologies’ Stockholders Vote in Favor of Annapurna Transaction
News| May 10, 2016
Avalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results
News| May 6, 2016
Avalanche Biotechnologies to Present at Upcoming Scientific Meetings
News| April 27, 2016
Avalanche Biotechnologies Reports Fourth Quarter and Fiscal 2015 Financial Results
News| March 3, 2016
Avalanche Biotechnologies to Present at Upcoming Investor Conferences
News| March 2, 2016
Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger
News| February 1, 2016
Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO
News| November 20, 2015
Avalanche Biotechnologies, Inc. Reports Third Quarter 2015 Financial Results
News| November 9, 2015
Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program
News| August 13, 2015
Avalanche Biotechnologies Awarded as Technology Pioneer by World Economic Forum
News| August 5, 2015
Avalanche Biotechnologies Announces Leadership Transition
News| July 23, 2015
Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration
News| June 15, 2015
Avalanche Biotechnologies Presents Three Posters at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
News| May 14, 2015
Avalanche Biotechnologies, Inc. Reports First Quarter 2015 Financial Results
News| May 13, 2015
Avalanche Biotechnologies to Present at Upcoming Scientific Meetings
News| April 28, 2015
Avalanche Biotechnologies and the University of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Medicines to Treat Color Blindness
News| March 25, 2015
Avalanche Biotechnologies to Host Analyst and Investor Day on March 25, 2015
News| March 18, 2015
Avalanche Biotechnologies, Inc. Reports Fourth Quarter and Fiscal 2014 Financial Results
News| March 5, 2015
Avalanche Biotechnologies to Present at Upcoming Investor Conferences
News| February 25, 2015
Avalanche Biotechnologies Prices Public Offering of $141.6 Million of Common Stock
News| January 8, 2015
Avalanche Biotechnologies Announces Proposed Public Offering of Common Stock and Partial Release of Lock-Up Agreements in Connection Therewith
News| January 5, 2015
Avalanche Biotechnologies to Present at the 26th Annual Piper Jaffray Healthcare Conference
News| November 26, 2014
Avalanche Biotechnologies to Present at the Jefferies Global Healthcare Conference
News| November 13, 2014
Avalanche Biotechnologies, Inc. Reports Third Quarter 2014 Financial Results
News| November 12, 2014
Avalanche Biotechnologies to Participate in Nomura's Biotechnology Conference
News| October 30, 2014
Avalanche Biotechnologies to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting
News| October 9, 2014
Avalanche Biotechnologies to Participate in Gene Therapy Panel at the BIO Investor Forum
News| October 1, 2014
Avalanche Biotechnologies, Inc., Appoints Industry Leader Roman G. Rubio, M.D., as Senior Vice President and Head of Translational Medicine
News| September 23, 2014
Avalanche Biotechnologies to Present at the NewsMakers in the Biotech Industry Conference
News| September 19, 2014
Avalanche Biotechnologies, Inc. Reports Second Quarter 2014 Financial Results
News| September 11, 2014
Avalanche Biotechnologies Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares
News| August 5, 2014
Avalanche Biotechnologies Prices Initial Public Offering of $102.0 Million of Common Stock
News| July 31, 2014
Avalanche Biotechnologies Announces Appointment of Samuel B. Barone, M.D., as Chief Medical Officer
News| July 1, 2014
Avalanche Biotechnologies Announces Appointment of Industry Veteran Linda C. Bain as Chief Financial Officer
News| May 20, 2014
Regeneron and Avalanche Biotechnologies Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology
News| May 5, 2014
Avalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing
News| April 22, 2014
Avalanche Raises Additional Funding in Follow-On Financing
News| November 22, 2013
Avalanche’s Novel Technology Restores Vision in Pre-Clinical Models of Blindness
News| June 12, 2013
Avalanche Biotechnologies, Inc. Announced That it Has Been Awarded Two Grants from the National Eye Institute to Fund Pre-clinical Studies Related to its Novel AAV Variant Technology
News| October 1, 2012
Avalanche Biotechnologies, Inc. and Lonza Announce Global Manufacturing Collaboration for Adeno-associated Viral Vectors for Gene Therapy
News| May 16, 2012
Avalanche Announces Collaboration with Lions Eye Institute and Merck to Develop AVA-101
News| November 1, 2011
Load More
Sort by Date:
ASGCT 2023

Intravitreal Delivery of Ixo-vec for Neovascular Age-Related Macular Degeneration Results in Widespread Expression of Aflibercept in Cynomolgus Monkey Eyes as Confirmed Using In-Situ Hybridization

Presentations| May 19, 2023
ASGCT 2023

Development of an Intravitreal (IVT) Gene Therapy for Geographic Atrophy (GA) by Overexpressing Complement Factor I (CFI) to Inhibit the Complement Cascade

Presentations| May 18, 2023
ASGCT 2023

Identification of Dose-Dependent Immune Landscape Signatures Following Administration of Ixo-vec in Non-Human Primates

Presentations| May 18, 2023
ASGCT 2023

CMC Strategies for AAV Gene Therapies for Highly Prevalent Diseases

Presentations| May 17, 2023
ASGCT 2023

Bilateral Ixo-vec NHP Tolerability and Efficacy Following a Staggered Dosing Interval between Eyes - Gene Therapy nAMD

Presentations| May 17, 2023
ASGCT 2023

Engineered Melanopsin Mutants for Optogenetic Vision Restoration

Presentations| May 17, 2023
ARVO 2023

Ixo-vec for the treatment of neovascular age-related macular degeneration: Nonclinical data in support of human equivalent dose of 6E10 vg/eye and staggered bilateral dosing

Presentations| April 22, 2023
Macula Society 2023

Ixo-Vec Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration

Presentations| February 13, 2023
Angiogenesis 2023

New Clinical Data on Overview of 2-Year Results with Detailed Analysis of Fluid Volatility and Outer Retinal Integrity

Presentations| February 11, 2023
OIS 2022

Ixo-Vec IVT Gene Therapy for nAMD

Presentations| December 3, 2022
Retina Society 2022

ADVM-022 (ixoberogene soroparvovec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration: End of Study Results from the 2-Year OPTIC Trial

Presentations| November 4, 2022
ASRS 2022

ADVM-022 (ixoberogene soroparvovec) Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update

Presentations| July 13, 2022
Load More

Investors

We’re pioneering innovation in the field of gene therapy. For our lead therapy ADVM-022, we are excited to see the potential for a single intravitreal injection to extend the treatment benefit from weeks to years in patients with wet AMD – even those who may have previously required frequent anti-VEGF injections. Our mission is to establish ocular gene therapy as a new standard of care for debilitating ocular diseases.

VISIT INVESTORS